Organon & Co. (OGN)
Automate Your Wheel Strategy on OGN
With Tiblio's Option Bot, you can configure your own wheel strategy including OGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OGN
- Rev/Share 18.0373
- Book/Share 2.8199
- PB 3.3228
- Debt/Equity 12.1364
- CurrentRatio 1.6516
- ROIC 0.1187
- MktCap 2435881420.0
- FreeCF/Share 1.2435
- PFCF 7.5362
- PE 4.3874
- Debt/Assets 0.659
- DivYield 0.064
- ROE 0.9913
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | OGN | Evercore ISI | Outperform | In-line | -- | -- | May 2, 2025 |
| Downgrade | OGN | JP Morgan | Neutral | Underweight | $18 | $20 | Sept. 6, 2024 |
News
Organon: Valuation Discount Offset By Structural Headwinds
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Negative
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside unless growth drivers emerge.
Read More
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
OGN vs. HQY: Which Stock Is the Better Value Option?
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Read More
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Negative
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.
Read More
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., Research Division Ethan Harris Brown - JPMorgan Chase & Co, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.
Read More
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Organon (OGN) Beats Q2 Earnings and Revenue Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Insights Into Organon (OGN) Q2: Wall Street Projections for Key Metrics
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Organon (OGN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Organon (OGN) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Contact Levi & Korsinsky by July 22, 2025 Deadline to Join Class Action Against Organon & Co.(OGN)
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2025.
Read More
OGN or MEDP: Which Is the Better Value Stock Right Now?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Deadline Soon: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Published: July 21, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 22, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between November 3, 2022 to April 30, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON ORGANON & CO. (OGN), CLICK HERE TO PARTICIPATE IN THE SECURITIES F.
Read More
DEADLINE TOMORROW: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action by July 22, 2025
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, July 21, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the “Class Period”).
Read More
OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2025.
Read More
The Gross Law Firm Notifies Shareholders of Organon & Co.(OGN) of a Class Action Lawsuit and an Upcoming Deadline
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
ORGANON & CO. (NYSE: OGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Organon & Co. Investors of Upcoming Deadline
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
Read More
INVESTOR DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OGN
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, inclusive (the “Class Period”). Captioned Lerner v. Organon & Co., No. 25-cv-12983 (D.N.J.), the Organon class action lawsuit charges Organon as well as certain of Organon's top executives with violations of the Securities Exchange Act of 1934. A previously filed complaint is captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.).
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options
Read More
OGN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – OGN
Published: July 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between November 3, 2022 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline.
Read More
ORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit
Published: July 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon (OGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between November 3, 2022 and April 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, July 18, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between November 3, 2022 to April 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
OGN SECURITIES FRAUD: Organon & Co. (NYSE:OGN) 27% Stock Drop Triggers Class Action Lawsuit – Contact BFA Law by July 22 Legal Deadline
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action.
Read More
OGN Deadline: OGN Investors with Losses in Excess of $100K Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between November 3, 2022 and April 30, 2025, both dates inclusive (the "Class Period"), of the important July 22, 2025 lead plaintiff deadline. So what: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
The Gross Law Firm Reminds Organon & Co. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGN
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Organon & Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , July 17, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the "Class Period"). Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
About Organon & Co. (OGN)
- IPO Date 2021-05-14
- Website https://www.organon.com
- Industry Drug Manufacturers - General
- CEO Kevin Ali
- Employees 10000